Momenta Pharmaceuticals Announces U.S. Court of Appeals Decision to Remand Enoxaparin Case Back to District Court
November 10 2015 - 2:56PM
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that
the United States Court of Appeals for the Federal Circuit (CAFC)
has vacated the Massachusetts district court’s summary judgment in
favor of Amphastar to the extent it was based on the scope of the
“safe harbor” under 271(e)(1). In reaching this decision, the CAFC
found that Amphastar’s alleged use of the Company’s patent is not
eligible for the 35 USC §271(e)(1) safe harbor. The CAFC remanded
this portion of the case to the Massachusetts district court for
further proceedings.
The CAFC separately affirmed the Massachusetts
district court’s summary judgment to the extent it relates to
infringement by Amphastar, Actavis and Teva under 35 USC §
271(g).
“We are pleased with the CAFC’s decision to
remand our case against Amphastar back to the District Court
allowing us to continue to pursue our enoxaparin patent
infringement litigation,” said Craig Wheeler, President and Chief
Executive Officer of Momenta.
About MomentaMomenta
Pharmaceuticals is a biotechnology company specializing in the
detailed structural and functional analysis of complex drugs and is
headquartered in Cambridge, MA. Momenta is applying its technology
to the development of generic versions of complex drugs, biosimilar
and potentially interchangeable biologics, and to the discovery and
development of novel therapeutics for oncology and autoimmune
indications.
To receive additional information about Momenta,
please visit the website at www.momentapharma.com, which does not
form a part of this press release. The company’s logo, trademarks,
and service marks are the property of Momenta Pharmaceuticals, Inc.
All other trade names, trademarks, or service marks are property of
their respective owners.
Forward Looking
StatementsStatements in this press release regarding
management's future expectations, beliefs, intentions, goals,
strategies, plans or prospects, including statements relating to
its beliefs and intentions related to the outcome of litigation
with Amphastar Pharmaceuticals and Teva Pharmaceuticals, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by terminology such as "anticipate,"
"believe," "could," "could increase the likelihood," "hope,"
"target," "project," "goals," "potential," "predict," "might,"
"estimate," "expect," "intend," "is planned," "may," "should,"
"will," "will enable," "would be expected," "look forward," "may
provide," "would" or similar terms, variations of such terms or the
negative of those terms. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors
referred to in the Company's Quarterly Report on Form 10-Q for the
quarter ended September 30, 2015 filed with
the Securities and Exchange Commission under the section
"Risk Factors," as well as other documents that may be filed by
Momenta from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and
factors, the Company's actual results may differ materially from
any future results, performance or achievements discussed in or
implied by the forward-looking statements contained
herein. Momenta is providing the information in this press
release as of this date and assumes no obligations to update the
information included in this press release or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Relations:
Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com
Media Relations:
Karen Sharma
MacDougall Biomedical Communications
1-781-235-3060
Momenta@macbiocom.com
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024